In vitro and in vivo models developed from human prostatic cancers;Modèles in vitro et in vivo développés à partir de cancers prostatiques humains

Progres en Urologie

Volumn 7, Issue 3, 1997, Pages 384-396

  Bladou, Franck ^a,b   Cleave, Martin E ^c   Penault Llorca, Frédérique ^b   Serment, Gérard ^a   Lange, Paul H ^d   Vessella, Robert L ^d  

^a Child and Adolescent Psychopathology Unit Salvator Hospital Public Assistance Marseille Hospitals University Aix Marseille II   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Athymic mice; Cell cultures; Experimental models; Prostatic cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR;

ANIMAL; BIOLOGY; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIVISION; COMPARATIVE STUDY; DISEASE MODEL; GENETICS; HUMAN; MALE; METASTASIS; MOLECULAR BIOLOGY; MOUSE; NUDE MOUSE; ONCOGENE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR; REVIEW;

ANDROGENS; ANIMALS; BIOLOGY; CELL DIVISION; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, NUDE; MOLECULAR BIOLOGY; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; ONCOGENES; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TUMOR CELLS, CULTURED;

EID: 0031155884     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (96)

1. ALBINI A., IWAMOTO Y., KLEINMAN H.K., et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res., 1987, 47, 3239-3245.
2. AKAKUEA K., BRUCHOVSKY N., GOLDENBERG S.L., RENNIE P.S., BUCKLEY A.R., SULLIVAN L.D. Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and serum prostate specific antigen. Cancer, 1993, 71, 2782-2790.
3. ANDREWS P.E., YOUNG C.Y.F., MONTGOMERY B.T., TINDALL DJ. Tumor-promoting phorbol ester down-regulates the androgen induction of prostate-specific antigen in a human prostatic adenocarcinoma cell line. Cancer Res., 1992, 52, 1525-1529.
4. BATSON O.V. The function of the vertebral veins and their role in the spread of metastasis. Ann. Surg., 1940, 112, 138-149.
5. BLADOU F., VESSELLA R.L., BUHLER K.R., ELLIS W.J., TRUE L.D., LANGE P.H. Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration. Int. J. Cancer, 1996, 67, 785-790.
6. BOSMA G.C., CUSTER R.P., BOSMA M.J. A severe combined immunodeficiency mutation in the mouse. Nature, 1983, 301, 527-530.
7. BROTHMAN A.R., LESHO L.J., SOMERS K.D., WRIGHT G.L., MERCHANT D.J. Phenotypic and cytogenetic characterization of a cell line derived from primary prostate carcinoma. Int. J. Cancer, 1989, 44, 898-903.
8. BRUCHOVSKY N., RENNIE P.S., COLDMAN A.J., GOLDENBERG S.L., TO M., LAWSON D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res., 1990, 50, 2275-2282.
9. CHING K.Z., RAMSEY E., PETTIGREW N., D'CUNHA R., JASON M., DODD J.G. Expression of mRNA for epidermal growth factor, transforming growth factor-a and their receptor in human prostate tissue and cell line. Mol. Cell. Biol., 1993, 126, 151-158.
10. CHUNG L.W.K., CLEAVE M.E., HSIEH J.T., HONG S.J., ZHAU H.E. Reciprocal mesenchymal-epithelial interaction affecting prostate cancer growth and hormonal responsiveness. Cancer Surveys, 1991, 11, 91-121.
11. CLAAS F.H.J., van STEENBURGGE G.J. Expression of HLA-like structures on a permanent human tumor line PC-93. Tissue Antigens, 1983, 21, 227-232.
12. COFFEY D.S., ISAACS IT. Requirements for an idealized animal model of prostatic cancer. In: Models of prostate cancer. Edited by G.P. Murphy. New-York: Alan R. Liss, Inc., pp 379-391, 1980.
13. COLOMBEL M., OLSSON C.A., NG P.Y., BUTTYAN R. Hormone-regulated apoptosis results from reentry of differentiated prostate cells into a defective cell cycle. Cancer Res., 1992, 52, 4313-4319.
14. COLOMBEL M, SYMMANS F., GIL S., O'TOOLE K.M., CHOPIN D., BENSON M., OLSSON C.A., KORSMEYER S., BUTTYAN R. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Amer. J. Pathol., 1993, 143, 390-400.
15. CSAPO Z., BRAND K., WALTHER R., FOKAS K. Comparative experimental study of the serum prostate specific antigen and prostae acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice. J. Urol., 1988, 140, 1032-1038.
16. ELLIS W.J., VESSELLA R.L., BUHLER K.R., BLADOU F., TRUE L.D., BIGLER S.A., CURTIS D., LANGE P.H. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin. Cancer Res., 1996, 2, 1039-1048.
17. FARBER E. Clonal adaptation during carcinogenesis. Biochem. Pharmacol., 1990, 39, 1837-1846.
18. FIDLER IJ. Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer and Metastasis Rev., 1986, 5, 29-49.
19. FONG C.J., SUTKOWSKI D.M., KOZLOWSKI J.M., LEE C. Utilization of the Boyden chamber to further characterize in vitro migration and invasion of benign and malignant human prostatic epithelial cells. Invasion and Metastasis, 1992, 12, 264-274.
20. FONG C.J., SHERWOOD E.R., MENDELSOHN J., LEE C., KOZLOWSKI J.M. Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha. Cancer Res., 1992, 52, 5887-5892.
21. GINGRICH J.R., TUCKER J.A., WALTHER P.J., DAY J.W., POULTON S.H., WEBB K.S. Establishment and characterization of a new human prostatic carcinoma cell line (DuPro-1). J. Urol., 1991. 146, 915-919.
22. GLEAVE M.E., HSIEH J.T., WU H.C., von ESCHENBACH A.C., CHUNG L.W.K. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res., 1992, 52, 1598-1605.
23. GLEAVE M.E., HSIEH J.T., GAO C.A., von ESCHENBACH A.C., CHUNG L.W.K. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res., 1991, 51, 3753-3761.
24. GLEAVE M.E., HSIEH J.T., Von ESCHENBACH A.C., CHUNG L.W.K. Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional stromal-epithelial interaction in prostate carcinoma growth and metastasis. J. Urol., 1992, 147, 1151-1159.
25. GLEAVE M.E., BOWDEN M, BRUCHOVSKY N., GOLDENBERG S.L., SULLIVAN L.D. Predictors of time to androgen-independent progression in the LNCaP prostate tumor model. J. Urol., 1994, 151, 458A. Abstract.
26. GLEAVE M.E., SANTO N., RENNIE P.S., GOLDENBERG S.L. BRUCHOVSKY N., SULLIVAN L.D. Echappement hormonal et hormonothérapie intermittente dans le modèle LNCaP de cancer prostatique humain. Prog. Urol., 1996, 6, 375-385.
27. GRAHAM S.D., POULTON S.H., LINDER J., WOODARD B.H., LYLES K.W., PAULSON D.F. Establishment of a long-term adenocarcinoma of the prostate cell line in the nude mouse. Prostate, 1985, 7, 369-376.
28. HARPER M., SIBLEY P., ROWLANDS A., BUTTIFANT L., BEACOCK C., GRIFFITHS K. Hormonal manipulation of the growth of a new transplantable prostatic cell line in athymic mice. Urol. Res., 1986, 14, 156A.
29. HENTTU P., LIAO S., VIHKO P. Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology, 1992, 130, 766-772.
30. HOEHN W., SCHROEDER F., RIEMANN J., JOEBSIS A., HERMANEK P. Human prostatic adenocarcinoma: some characteristics of a serially transplantable line in nude mice (PC-82). Prostate, 1980, 1, 95-104.
31. HOEHN W., WAGNER M., RIEMANN J.F., HERMANEK P., WILLIAMS E., WALTHER R., SCHRUEFFER R. Prostatic adenocarcinoma PC EW, a new human tumor line transplantable in nude mice. Prostate, 1984, 5, 445-452.
32. HOROSZEWICZ J, LEONG S., CHU T, WAJSMAN Z. et al. The LNCaP cell line: a new model for studies on human prostatic carcinoma. Prog. Clin. Biol. Res., 1980, 37, 115-132.
33. HSIEH J.T., WU H.C., GLEAVE M.E., et al. Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline. Cancer Res., 1993, 53, 2852-2857.
34. HUGGINS C., HODGES C.V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1941, 1, 293-297.
35. HUGGINS C., STEVENS R.E., HODGES C.V Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg., 1941, 43, 209-223.
36. IIZUMI T., YAZAKI T., KANOH S., KONDO I., KOISO K. Establishment of a new prostatic carcinoma cell (TSU-PR1). J. Urol., 1987, 137, 1304-1306.
37. ISAACS J.T., COFFEY D.S. Model systems for the study of prostatic cancer. Clinics in Oncology. 1983, 2, 479-498.
38. ITO Y., NAKAZATO Y. A new serially transplantable human prostatic cancer (Honda) in nude mice. J. Urol., 1984, 132, 384-387.
39. ITO Y., MASHIMO S., NATAZATO Y., TAKIKAWA H. Hormone dependency of a serially transplantable human prostatic cancer (Honda) in nude mice. Cancer Res., 1985, 45, 5058-5063.
40. KAIGHN M., NARAYAN S.K., OHNUKI Y., LECHNER J.F., JONES L. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol., 1979, 17, 16-23.
41. KOZLOWSKI J.M., MCEWAN R., KEER H., SENSIBAR J., ET AL. Prostate cancer and the invasive phenotype: Application of the in vivo and in vitro approaches In: Fidler IJ, Nicholson G (eds) Tumor Progression and Metastasis. Alan R. Liss Inc., New York, 1988, pp 189-231.
42. KYPRIANOU N., ENGLISH H.F., ISAACS J.T. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res., 1990, 50, 3748-3753.
43. LEE C., SHEVRIN D.H., KOZLOWSKI J.M. In vivo and in vitro approaches to study metastasis in human prostatic cancer. Cancer Metastasis Rev., 1993, 12, 21-28.
44. LIM D.J., LIU X.L, SUTKOWSKI D.M., BRAUN E.J., LEE C., KOZLOWSKI J.M. Growth of an androgen-sensitive human prostate cancer cell line, LNCaP, in nude mice. Prostate, 1993, 22, 109-118.
45. LIU A.Y., COREY E., BLADOU F., LANGE P.H., VESSELLA R.L. Prostatic cell lineage markers: emergence of bcl2+ cells of human prostate cancer xenograft LuCaP 23 following castration. Int. J. Cancer, 1996, 65, 85-89.
46. LOOP S.M., ROZANSKI T.A., OSTENSON R.C. Human primary prostate tumor cell line ALVA 31 a new model for studying the hormonal regulation of prostate tumor cell growth. Prostate, 1993, 22, 93-108.
47. MARIN M.C., HSU B., MEYN R.E., DONEHOWER L.A., ELNAGGAR A.K., MCDONNELL T.J. Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. Oncogene. 1994, 9, 3107-3112.
48. MCCUNE J.M., NAMIKAWA R., KANESHIMA H., SHULTZ L.D., LIEBERMAN M., WEISSMAN I.L. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science, 1988, 241, 1632-1639.
49. MCDONNELL T.J., TRONCOSO P., BRISBAY S.M., LOGOTHETIS C., CHUNG L.W.K., HSIEH J.T., TU S.M., CAMPBELL M.L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 1992, 52, 6940-6944.
50. MILLER G.J., STAPLETON G.E., FERRARA J.A., LUCIA M.S., PFISTER S., HEDLUND T.E., UPADHYA P. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha, 25-dihydroxyvitamin D3. Cancer Res., 1992, 52, 515-520.
51. MILLER J.I., AHMANN F.R., DRACH G.W., EMERSON S.S., BOTTACCINI M.R., The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J. Urol., 1992, 147, 956-961.
52. MORRIS G.L., DODD J.G. Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines J. Urol., 1990, 143, 1272-1274.
53. MOSIER D.E., GULIZIA R.J., BAIRD S.M., WILSON D.B. Transfer of a functional humane immune system to mice with severe combined immunodeficiency. Nature, 1988, 335, 256-259.
54. MUELLER B.M., REISFELD R.A. Potential of the scid mouse as a host for human tumors. Cancer and Metastasis Rev., 1991, 10, 193-200.
55. MURAKI J., ADDONOZIO J., CHOUDHURY M. FISCHER J., ESHGHI M., DAVIDIAN M., SHARPPIRO L., WILMOT P, NAGAMATSU G., CHIAO J. Establishment of new human prostatic cancer cell (JCA-1). Invest. Ural., 1990, 36, 79-84.
56. NAGABHUSHAN M., MILLER C.M., PRETLOW T.P. et al. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar Cancer Res., 1996, 56, 3042-3046.
57. NAKAMOTO T., CHANG C.S., LI A.K., CHODAK G.W. Basic fibroblast growth factor in human prostate cancer cells. Cancer Res., 1992, 52, 571-577.
58. NAKHLA A.M., ROSNER W. Characterization of ALVA 41 cells, a new human prostatic cancer cell line. Steroids, 1994, 59, 586-589.
59. NARAYAN P., DAHIYA R. Establishment and characterization of a human primary prostatic adenocarcinoma line (ND-1). J. Urol., 1992, 148, 1600-1604.
60. NISHIJIMA Y., UCHIDA K., KOISO K., NEMOTO R. Clinical significance of the vertebral vein in prostate cancer metastasis. In: Prostate cancer and bone metastasis Edited by J.P. Karr and H. Yamanaka. New York: Plenum Press, 1992, 93-100.
61. OKADA K, SCHOEDER F.H. Human prostatic carcinoma in cell culture: preliminary report on the development and characterization of an epithelial cell line (EB-33). Urol. Res., 1974, 2, 111-121.
62. PASSANITI A., ISAACS J.T., HANEY J.A, ADLER S.W., CUJDIK T.J., LONG P.V., KLEINMAN H.K. Stimulation of human prostatic carcinoma tumor growth in athymic mice and control of migration in culture by extracellular matrix. Int J. Cancer, 1992, 51, 318-324.
63. PIETRZKOWSKI Z., MULHOLLAND G., GOMELLA L., JAMESON B.A., WERNICKE D., BASERGA R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res., 1993, 53, 1102-1106.
64. PONTES J.E., CHOE B., ROSE N., PIERCE J.M. Immunochemical identification of prostatic epithelial cells in culture. Invest. Urol., 1979, 16, 483-485.
65. PRETLOW T.G., DELMORO C.M., DILLEY G.G., SPADAFORA C.G., PRETLOW T.P. Transplantation of human prostatic carcinoma into nude mice in Matrigel. Cancer Res., 1991, 51, 3814-3817.
66. PRETLOW T.G., WOLMAN S.R., MICALE M.A., et al.: Xenografts of primary human prostatic carcinoma. JNCI, 1993, 85, 394-398.
67. RIEGMAN P.H.J., VLIETSTRA R J., van der KORPUT J.A.G.M., BRINKMANN A.O., TRAPMAN J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol. Endocrinol., 1991, 5, 1921-1930.
68. RUIZEVELD de WINTER J.A., van WEERDEN W.M., FABER P.W., van STEENBRUGGE G.J., TRAPMAN J., BRINKMANN A.O., van der KWAST T.H. Regulation of androgen receptor expression in the human heterotransplantable prostate carcinoma PC-82. Endocrinology. 1992, 131, 3045-3050.
69. RYGAARD J., POVLSEN C.O. Heterotransplantation of human malignant tumor to nude mouse. Acta Pathol. Microbiol. Scand., 1969, 77, 758-760.
70. SCHILLER C.D., SCHNEIDER M.R., HARTMANN H., GRAF A.H., KLOCKER H., BARTSCH G. Growth-stimulating effect of adrenal androgens on the R3327 Dunning prostatic carcinoma. Urol. Res., 1991, 19, 7-13.
71. SCHUURMANS A.L., BOLT J., MULDER E. Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP. Prostate, 1988, 12, 55-63.
72. SCHUURMANS A.L., BOLT J., VELDSCHOLTE J., MULDER E. Regulation of growth of LNCaP human prostate tumor cells by growth factors and steroid hormones. J. Steroid Biochem. Mol. Biol., 1991, 40, 193-197
73. SHEVRIN D.H., KUKREJA S.C., GHOSH L., LAD T.E. Development of skeletal metastasis by human prostate cancer in athymic nude mice. Clin. Exp. Metastasis, 1988, 6, 401-409.
74. SHEVRIN D.H., CORNY K.I., KUKREJA S.C. Patterns of metastasis by the human prostate cancer cell line PC-3 in athymic nude mice. Prostate, 1989, 15, 187-194.
75. SITARAS N.M., SARIBAN E., BRAVO M., PANTAZIS P., ANTONIADES H.N. Constitutive production of platelet growth factor-like proteins by human prostate carcinoma cell lines. Cancer Res., 1988, 48, 1930-1935.
76. Van STEENBRUGGE G.J., GROEN M., ROMIJN J.C., SCHRODER F.H. Biological effects of hormonal treatment regimens on a transplantable human prostatic tumor line (PC-82). J. Urol., 1984, 131, 812-817.
77. Van STEENBRUGGE G., GROEN M., BOLT-de VRIES J., ROMIJN J., SCHROEDER F Human prostate cancer (PC-82) in nude mice: a model to study androgen regulated tumor growth. Prog. Clin. Biol. Res., 1985, 185A, 23-50.
78. STEPHENSON R.A., DINNEY C.P.N., GOHJI K., ORDONEZ N.G., KILLION J.J., FIDLER I.J. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J. Natl. Cancer Inst., 1992, 84, 951-957.
79. STONE K.R., MICKEY D.D., WUNDERLI H., MICKEY G.H., PAULSON D. Isolation of a human prostate carcinoma cell line (DU-145). Int. J. cancer. 1978, 21, 274-281.
80. THALMANN G.N., ANEZIMIS P.E., CHANG S.H., et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res., 1994, 54, 2577-2581.
81. THIEDE K., MOMBURG F., ZANGEMEISTER U., SCHLAG P., SCHIRRMACHER V. Growth and metastasis of human tumors in nude mice following tumor-cell moculation into a vascularized polyurethane sponge matrix. Int. J. Cancer, 1988, 42, 939-945.
82. TILLEY W.D., WILSON C.M., MARCELLI M. MCPHAUL M.J. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res., 1990, 50, 5382-5386.
83. VELDSCHOLTE J., VOORHORST-OGINK M.M., BOLT-de-VRIES J., van-ROOIJ H.C. TRAPMAN J., MULDER E. Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids. Biochem. Biophys. Acta, 1990, 1052, 187-194.
84. WAINSTEIN M.A., HE F., ROBINSON D., et al.: CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res., 1994, 54, 6049-6052.
85. WANG M. STEARNS M.M. Isolation and characterization of PC-3 human prostatic tumor sublines which preferentially metastasize to select organs in SCID mice. Differentiation, 1991, 48, 115-125.
86. WARE J.L., PAULSON D.F., MICKEY G.H. WEBB K.S. Spontaneous metastasis of cells of the human prostate carcinoma cell line PC-3 in athymic nude mice. J. Urol., 1982, 128, 1064-1067.
87. Van WEERDEN W.M., van STEENBRUGGE G.J., van KREUNINGEN A., MOERINGS E.P., deJONG F.H., SCHRODER F.H. Assessment of the critical level of androgen for growth response of transplantable human prostatic carcinoma (PC-82) in nude mice. J. Urol., 1991, 145, 631-634.
88. Van WEERDEN W.M., BIERINGS G.J., van STEENBRUGGE G.J., de JONG F.H., SCHRODER F.H. Adrenal glands of mouse and rat do not synthesize androgens. Life Sci., 1992, 50, 857-861.
89. van WEERDEN W.M., van KREUNINGEN A., ELISSEN N.M.J., deJONG F.H., van STEENBRUGGE G.J., SCHRODER F.H. Effects of adrenal androgens on the transplantable human prostate tumor PC-82. Endocrinology, 1992, 131, 2909-2913.
90. van WEERDEN W.M., van KREUNINGEN A., ELISSEN N.M.J., VERMEIJ M., deJONG F.H., van STEENBRUGGE G.J., SCHRODER F.H. Castration induced changes in morphology, androgen levels, and proliferation activity of human prostate tissue grown in athymic mice. Prostate, 1993, 23, 149-164.
91. van WEERDEN W.M., de RIDDER C.M.A., VERDAASDONK C.L., ROMIJN J.C., van der KWAST T.H., SCHRODER F.H., van STEENBRUGGE G.J. Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am. J. Pathology, 1996, 149, 1055-1062.
92. WILDING G., VALVERIUS E., KNABBE C., GELMANN E.P. Role of transforming growth factor-alpha in human prostate cancer cell growth. Prostate, 1989, 15, 1-12.
93. WRIGHT G.L., HALEY C.L., CSAPO Z., van STEENBRUGGE G.J. Immunohistochemical evaluation of the expression of prostate tumor-association markers in the nude mouse human prostate carcinoma heterotransplant lines PC-82, PC-EW, and PC-EG. Prostate, 1990, 17, 301-316.
94. WU H.C, HSIEH J.T., GLEAVE M.E., et al. Derivation of androgen-independent human LNCaP prostate cancer sublines: role of bone stromal cells. Int. J. Cancer, 1994, 57, 406-410.
95. YOUNG C.Y.F., ANDREWS P.E., MONTGOMERY B.T., TINDALL D.J. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry, 1992, 31, 818-824.
96. YUAN S., TRACHTENBERG J., MILLS G.B., BROWN T.J., XU F., KEATING A. Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC3) transfected with a human androgen receptor complementary DNA. Cancer Res., 1993, 53, 1304-1311.